Interview: Whaijen Soo Managing, Director, Supra Integration and Incubation…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s…
Supra Integration and Incubation Center (Si2C), Taiwan
Last updated: 13.02.2014
The Supra Integration and Incubation Center (Si2C), the first government-sponsored agency in Taiwan dedicated to promoting the nation’s biotechnology industry, was formally inaugurated Nov. 1, according to Si2C organizer the Science and Technology Advisory Group of the Executive Yuan.
“The primary purpose of our center is to allocate resources to the nation’s biotech industry and pharmaceutical companies, so that they can develop new and innovative biotech products,” said Soo Whai-jen, managing director of the Si2C.
In addition, Soo added, the Si2C will provide Taiwan’s biotech companies with legal counsel, help them with patent applications, and offer them technical assistance.
STAG Vice Convener and Minister without Portfolio Cyrus C. Y. Chu said that with the establishment of the Si2C, the government set up all “four pillars” needed to develop a complete value chain for the nation’s biotech industry.
The other three pillars, Chu said, are creating the Taiwan Food and Drug Administration, a task accomplished in 2009; setting up the NT$60 billion (US$2.03 billion) Biotech Venture Capital; and underwriting research investments in genetic translation and rapid prototyping production of medical devices.
These efforts are part of the government’s 2009 plan to double the biotech industry’s output value in four years, according to the STAG.
“Erecting these four pillars is only the first step,” Chu said. “The government still needs to respond to the needs of industry and help firms overcome many difficulties.”
Soo, a former researcher and executive for Hoffmann-La Roche Ltd. and Shire PLC, both in the United States, assumed his present position after he was strenuously recruited by STAG.
STAG said it is also working to have Shaw T. Chen, deputy director of U.S. Food and Drug Administration’s Office of Drug Evaluation, join the Si2C team as soon as possible. (HZW)
Interviews
Related
Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s…
Johnsee Lee – Chairman & CEO & Eric Yang – VP, Quark…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their…
Louis Cheng – CEO, Leadgene Biomedical, Taiwan
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody…
Johnsee Lee – Chairman, Taiwan Bio Industry Organization; President &…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s…
First Impressions / Taiwanese Pharma
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that…
Report / New Taiwan Pharma Report November 2019 Out Now
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an…
APAC / Taiwanese Pharma Looking Locally for International Opportunities
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market,…
Talent / Multinationals' HR Strategies in Taiwan
All country managers of multinational pharma companies need to strike the balance between having a global outlook…
Stanley Huang – Founder & Managing Director, Nutrarex Biotech, Taiwan
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively…
APAC / Taiwan's New Southbound Policy: Enhancing Regional Ties
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland…
Company Profile / iXensor, Taiwan
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which…
Mark Yang – CEO, GaleMed, Taiwan
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned…
